Business
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical CenterPatient
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"text","content":"The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical CenterPatient enrollment has begun; interim results anticipated by September, 2025In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tick-borne, potentially life-threatening illnessCase studies in recent medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed patients who have relapsing babesiosis and for whom prior treatment has failedTotal cumulative accessible market through the end of patent protection in the U.S. for ARAKODA® (tafenoquine) for babesiosis is approximately 400,000 patients WASHINGTON, July 19, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has signed clinical trial agreements with all three of the planned clinical trial sites for the Tafenoquine for Babesiosis study now enrolling. Tufts Medical Center, Yale University, and Rhode Island Hospital will conduct the world's first randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. At least 24, and potentially up to 33, hospitalized patients diagnosed with relapsing babesiosis will be recruited for the study, with interim results anticipated by September, 2025. “Babesiosis is becoming a top concern within the infectious diseases healthcare community given the fact that accurate diagnosis and treatment are crucial to preventing progression to very serious phases of this illness,” said Dr. Geoff Dow, chief executive officer of 60 Degrees Pharmaceuticals. “Today, a patient who reaches the relapsing stage of babesiosis has few effective treatment options. The Tafenoquine for Babesiosis clinical trial currently enrolling patients is anticipated to shed new light on how best to address the babesiosis treatment needs of this group. The team at 60 Degrees Pharmaceuticals is pleased to partner with Tufts Medical Center, Yale University, and Rhode Island Hospital – three of the world’s leading medical centers – in this effort.” A recently published study suggested that taf...